Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regenx Science Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This filing is assigned to 1 distinct examiner, LI, WENHAN, who is the busiest examiner with 1 pending action. This 1 to 1 relationship between the pending action and the examiner indicates a very specific and singular point of engagement with the patent office for the company's current Biotechnology & Pharmaceuticals interests.
The prosecution is concentrated in 1 distinct art unit, matching the count of examiners and pending actions. For a practitioner, this concentration means that the company's current success in the Biotechnology & Pharmaceuticals sector is entirely dependent on the review of LI, WENHAN. The lack of multiple art units or examiners suggests a narrow administrative footprint, which may simplify communication but also increases the impact of a single examiner's perspective on the portfolio's immediate outcomes. This focused approach ensures that all current intellectual property efforts are channeled through a single, specialized path within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, WENHAN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837144 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | LI, WENHAN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837144 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | LI, WENHAN | 1614 | §103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenx Science Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Wenhan Li has the most, with 1 of Regenx Science Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
